clinical trial · NCT04814368
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
Knee OsteoarthritiscanakinumabLNA043Placebo to canakinumab
brief summary
The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).
started
Aug 27, 2021
primary completion
Jun 24, 2024
completion
Jun 24, 2024
last updated
Oct 24, 2025
detailed description
This was a non-confirmatory, randomized, four arm, placebo-controlled, participant-, investigator and sponsor-blinded study in participants with symptomatic knee OA with synovial inflammation.
official title
A Randomized, Four-arm, Canakinumab Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol